Search Within

Matthew J Matasar

  1. "Molecular Imaging and Therapy Service"
  2. "Radiology, Department of"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (18)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (46)
  2. Department of Medicine (46)
  3. Hematologic Malignancies, Division of (46)
  4. Lymphoma (46)
  5. Molecular Imaging and Therapy Service (46)
  6. Radiology, Department of (46)

More Groups

People
  1. Andrew Zelenetz (44)
  2. Heiko Schoder (42)
  3. David Straus (39)
  4. Paul Hamlin (39)
  5. Anita Kumar (38)
  6. Alison Moskowitz (37)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (4)
  4. 2021 (8)
  5. 2020 (3)
  6. 2019 (5)

More Years

Publications
  1. Blood (22)
  2. Hematological Oncology (5)
  3. Journal of Clinical Oncology (5)
  4. Haematologica (2)
  5. American Journal of Hematology (1)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (23)
  2. Wiley Blackwell (6)
  3. American Society of Clinical Oncology (5)
  4. Ferrata Storti Foundation (2)
  5. American Association for Cancer Research (1)
  6. Elsevier Inc. (1)

More Publishers

Results (46)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schòˆder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save